BlinkLab partners with Erasmus MC for therapy evaluation

Australian-listed digital healthcare company BlinkLab (ASX:BB1) announced a landmark academic research agreement with the Erasmus University Medical Centre Rotterdam, a European medical research institution.

The collaboration marks a milestone for BlinkLab, signalling its expansion beyond diagnostic assessment into the critical areas of therapy evaluation, treatment monitoring, and the development of future digital endpoints for pharmaceutical and interventional studies.

The joint programme is specifically designed to investigate treatment-related changes in behavioural and neurodevelopmental function in patients with activated PI3K Delta Syndrome.

APDS is a rare inborn error of immunity that is increasingly recognised for its strong association with neurodevelopmental and behavioural symptoms, including autism.

To support the project, BlinkLab will deploy its novel neurometric technology to capture objective, quantifiable measures of patient responses to treatment—a clinical outcome that has previously been exceptionally difficult to achieve.

Commenting on the announcement, Dr Henk-Jan Boele, Managing Director and CEO of BlinkLab, highlighted the transformative nature of the partnership.

He emphasised that as global drug development increasingly shifts towards biologically defined neurodevelopmental conditions, BlinkLab aims to remain at the forefront of digital health.

Dr Aleksandra Badura, Principal Investigator at Erasmus MC, also welcomed the collaboration, noting that APDS affects both immunological and neurodevelopmental functions.

The study will combine Erasmus MC's clinical expertise with BlinkLab’s innovative mobile platform to establish precise, objective measurement tools for therapeutic and treatment studies moving forward.

At the time of reporting, BlinkLab’s share price was $0.66.